RxDoctor Payments DataLook up a doctor →

Alexandra Lansky, MD

Cardiology · New Haven, CTNPI 1336227172

Payments from drug & device makers

$3,846,272in general payments, 2019–2025

Across 264 payments — averaging $14,569 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Trireme Medical LLC$892K
  • Siemens Medical Solutions USA, Inc.$692K
  • Cleerly, Inc.$603K
  • Bard Peripheral Vascular, Inc.$466K
  • Surmodics, Inc.$417K
  • Contego Medical, Inc$390K
  • plus $387K from 18 others
$14,250in research payments, 2019–2025

Across 1 payment — averaging $14,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medalliance LLC$14K

What the payments were for

  • Consulting fees$67,71835%
  • Speaking & faculty fees$81,67042%
  • Travel & lodging$42,96322%
  • Food & beverage$2,9041%
  • Education$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,846,272 in reported general payments places this provider in the 95th percentile of 28 cardiology providers in Connecticut.

See all cardiology providers in Connecticut

Medicare billing

Part B allowed, 2024
$4,990
Medicare patients
26
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$26,152
FarxigaDapagliflozin Propanediol17$16,121
Valsartan24$843
Metoprolol Succinate49$720
Atorvastatin Calcium67$528
Rosuvastatin Calcium37$354
ClopidogrelClopidogrel Bisulfate25$295
Losartan Potassium42$284
Ezetimibe21$169
Isosorbide Mononitrate ErIsosorbide Mononitrate11$157
Amlodipine Besylate28$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$17,167$16,12117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 cardiology providers in Connecticut.

Other cardiology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →